Justin Klein, MD, JD
Justin was appointed to the VytronUS Board of Directors in 2009. He serves on the Boards of Directors for Advanced Cardiac Therapeutics, Ajax Vascular, Cartiva, PhaseBio Pharmaceuticals, Relievant Medsystems, Senseonics, Topera, and VertiFlex, and has co-sponsored NEA's investments in Carticept Medical, ExploraMed, NeuroPace, and Nevro. Justin joined NEA in 2006 and is a Partner on the healthcare team focusing on medical device, healthcare technology, and biopharmaceutical company investments. Justin's past board memberships and investments include CV Ingenuity, TriVascular, and Ulthera. Justin is also a member of the Advisory Boards for the National Venture Capital Association's Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC), as well as a member of AdvaMed's Business Development Committee. Prior to NEA, Justin worked for the Duke University Health System. Justin earned an A.B. in Economics, a B.S. in Biological Anthropology and Anatomy, and an M.D. from Duke University, as well as a J.D. from Harvard Law School. Justin has also served as a member of the Board of Trustees of Duke University.
Hank was appointed to the VytronUS board of directors in 2014 as a representative of BioStar Ventures. Hank serves as a Director of BioStar, which includes representing the firm as a Senior Advisor or Board Member to various BioStar portfolio companies. He also is a member of the Board of Directors of Hill Rom, Inc., Element Science, and Corpak Medical. Hank previously served as Chief Executive Officer for Boston Scientific. Before being named CEO in October 2011, Hank was Executive Vice President and President of the Cardiology, Rhythm, and Vascular (CRV) Group and was responsible for the Company’s Interventional Cardiology and Cardiac Rhythm Management businesses and its Endovascular Unit, which includes the Peripheral Interventions, Neurovascular, Imaging, and Electrophysiology businesses. Both within and before joining Boston Scientific, Hank held a variety of management positions in sales and marketing for SCIMED, Charter Medical Corporation, and Control Data Corporation. Hank began his career at the United States Air Force Academy Hospital and later was Healthcare Planner, Office of the Surgeon General, for the United States Air Force Medical Service. Hank earned a B.S. and M.B.A. from Virginia Polytechnic Institute and State University. Hank has served on several industry boards, including the Board of Directors of the Global Health Exchange.
David was appointed to the VytronUS Board of Directors in 2014. David joined Apple Tree Partners in 2012 and is a Partner focusing on medical device opportunities. Prior to Apple Tree, David was Executive Vice President, Chief Financial Officer of HeartWare International, Inc. from 2005 through 2011, and assumed the additional responsibilities of Chief Operating Officer during HeartWare’s global commercialization phase for the period from 2008 through 2011. Prior to HeartWare, David practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions, and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies including Coal & Allied Limited, a publicly traded subsidiary of the Rio Tinto Group of companies. David also serves on the Board of Directors of Tendyne Holdings, Inc. David earned a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Masters of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia).
John joined VytronUS in 2015 as the President and Chief Executive Officer. John has more than twenty-five years of medical device experience, including more than fifteen years as Chief Executive Officer of large and small organizations. Prior to VytronUS, John was President and Chief Executive Officer of Endoscopic Technologies, Inc. a leader in minimally invasive and endoscopic cardiac ablation, valve repair or replacement, and coronary bypass surgical technology. Endoscopic Technologies was acquired by AtriCure in late 2013. Previously, John served as President and Chief Executive Officer of R2 Technology Inc., the pioneer and leader in computer-aided detection of breast cancer and lung abnormalities, until Hologic Inc. acquired the company in 2006. Before joining R2 Technology, John was the President of the Ultrasound group at Siemens Healthcare for five years, where he led the acquisition and integration of Acuson Inc. and subsequent growth to $1 Billion revenue. John earned a B.S. in Biomedical Engineering from Rensselaer Polytechnic Institute and an M.S. in Engineering Sciences from the Thayer School of Engineering at Dartmouth College.
Roy was appointed to the VytronUS Board of Directors in 2010. He is currently a member of the Boards of Directors of Coherex, Advanced Cardiac Therapeutics, and BioSig Technologies and has served on the boards of Volcano and Tomotherapy. From 2004 through 2008, Roy served as the Worldwide President of Biosense Webster, Inc. for Johnson & Johnson. Roy joined Johnson & Johnson as the U.S. President of Biosense Webster, Inc. in 1997. From 1992 through 1997, Roy served in a variety of senior management positions at Sorin Biomedical, Inc., including President and Chief Executive Officer. From 1989 to 1992, Roy served in Vice President roles with Shiley, a division of Pfizer Inc. Roy earned a B.S. in Mechanical Engineering from Purdue University and an M.B.A. from Illinois Benedictine College.